APA (7th ed.) Citation

Yang, L., Qiu, Q., Wang, J., Wen, Y., Li, H., Liang, R., . . . Niu, T. (2025, June). Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed/refractory multiple myeloma and lymphoma. Signal Transduction and Targeted Therapy.

Chicago Style (17th ed.) Citation

Yang, Linyu, et al. "Preclinical and First-in-human of Purinostat Mesylate, a Novel Selective HDAC I/IIb Inhibitor, in Relapsed/refractory Multiple Myeloma and Lymphoma." Signal Transduction and Targeted Therapy Jun. 2025.

MLA (9th ed.) Citation

Yang, Linyu, et al. "Preclinical and First-in-human of Purinostat Mesylate, a Novel Selective HDAC I/IIb Inhibitor, in Relapsed/refractory Multiple Myeloma and Lymphoma." Signal Transduction and Targeted Therapy, Jun. 2025.